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1. INTRODUCTION {#mbo3988-sec-0001}
===============

Chronic pulmonary disease (CPD) due to opportunistic infections of nontuberculous mycobacterial (NTM) pathogens from environmental sources has become an increasingly recognized global public health problem (Kendall & Winthrop, [2013](#mbo3988-bib-0036){ref-type="ref"}; Prevots & Marras, [2015](#mbo3988-bib-0056){ref-type="ref"}). At least forty NTM spp. are associated with CPD (Daley & Griffith, [2010](#mbo3988-bib-0013){ref-type="ref"}). The ubiquitous slow‐growing *Mycobacterium kansasii* (*Mk*) is among the six most common NTM spp. associated with CPD in the United States and many other areas of the world, where it is often surpassed only by the *Mycobacterium avium* complex (Davies, Roberts, Kaul, Klein, & Milburn, [2012](#mbo3988-bib-0015){ref-type="ref"}; Hoefsloot et al., [2013](#mbo3988-bib-0032){ref-type="ref"}; Mirsaeidi, Farshidpour, Allen, Ebrahimi, & Falkinham, [2014](#mbo3988-bib-0050){ref-type="ref"}; Prevots & Marras, [2015](#mbo3988-bib-0056){ref-type="ref"}). The burden of *Mk* infections is not surprising given that the risk factors include HIV infection, pharmacological immunosuppression, chronic obstructive pulmonary disease (COPD), malignancy, bronchiectasis, and previous mycobacterial disease (Maliwan & Zvetina, [2005](#mbo3988-bib-0047){ref-type="ref"}; Prevots & Marras, [2015](#mbo3988-bib-0056){ref-type="ref"}). *Mk* is often present in human‐made water systems, where it forms resilient biofilms (Chakraborty & Kumar, [2019](#mbo3988-bib-0008){ref-type="ref"}; Kwenda et al., [2015](#mbo3988-bib-0038){ref-type="ref"}; Vaerewijck, Huys, Palomino, Swings, & Portaels, [2005](#mbo3988-bib-0072){ref-type="ref"}). Infection generally originates following inhalation, aspiration, ingestion, or local inoculation (Griffith et al., [2007](#mbo3988-bib-0029){ref-type="ref"}; Vaerewijck et al., [2005](#mbo3988-bib-0072){ref-type="ref"}). Although person‐to‐person transmission has not been reported, some studies suggest that it might be possible, and the potential emergence of strains with an epidemiologically meaningful person‐to‐person transmission capacity is a concern (Ricketts, O\'Shaughnessy, & van Ingen, [2014](#mbo3988-bib-0059){ref-type="ref"}).

*Mycobacterium kansasii* has seven subtypes, with subtype 1 being by far the most prevalent in human isolates, followed by subtype 2. The remaining subtypes are recovered from environmental samples almost exclusively (Bakula, Safianowska, Nowacka‐Mazurek, Bielecki, & Jagielski, [2013](#mbo3988-bib-0004){ref-type="ref"}; Picardeau, Prod\'Hom, Raskine, LePennec, & Vincent, [1997](#mbo3988-bib-0055){ref-type="ref"}; Taillard et al., [2003](#mbo3988-bib-0068){ref-type="ref"}; Tortoli, [2003](#mbo3988-bib-0070){ref-type="ref"}). *Mk* has a relatively close phylogeny to the *Mycobacterium tuberculosis* (*Mtb*) complex and its related *Mycobacterium canettii* clade, and an *Mk*‐like opportunistic pathogen is believed to be an *Mtb* complex ancestor (Minnikin et al., [2015](#mbo3988-bib-0049){ref-type="ref"}; Veyrier, Pletzer, Turenne, & Behr, [2009](#mbo3988-bib-0074){ref-type="ref"}; Wang et al., [2015](#mbo3988-bib-0076){ref-type="ref"}). Moreover, *Mk* has been considered as a possible model to explore the evolutionary transition from the environmental opportunistic pathogen lifestyle to the obligate pathogen lifestyle seen in the genus, and as a surrogate of *Mtb* for tuberculosis (TB) pathogenesis studies (Minnikin et al., [2015](#mbo3988-bib-0049){ref-type="ref"}; Wang et al., [2015](#mbo3988-bib-0076){ref-type="ref"}).

The CPD caused by *Mk* resembles TB and its mortality is associated with comorbidities and treatment failure (Ehsani, Reddy, Mosunjac, Kraft, & Guarner, [2015](#mbo3988-bib-0023){ref-type="ref"}; Evans et al., [1996](#mbo3988-bib-0025){ref-type="ref"}; Hirashima et al., [2014](#mbo3988-bib-0031){ref-type="ref"}; Maliwan & Zvetina, [2005](#mbo3988-bib-0047){ref-type="ref"}). Relapses occur often (≈10%) and cure rates are only 80%--90% (Davies et al., [2012](#mbo3988-bib-0015){ref-type="ref"}; Mirsaeidi et al., [2014](#mbo3988-bib-0050){ref-type="ref"}; Santin et al., [2009](#mbo3988-bib-0064){ref-type="ref"}). The prevalence of *Mk* CPD remains under‐recognized, particularly in high TB‐HIV burden areas, due to overlapping features with TB, lack of proper diagnosis, and absence of compulsory reporting policy. Nevertheless, it is clear that *Mk* CPD continues to rise with the enduring HIV epidemic and the increase of other predisposing factors in the population (e.g., immunosuppression and COPD). In addition, infection of skin and subcutaneous tissue is not uncommon, and, like primary lung infection, may lead to disseminated disease in people with a compromised immune system or other vulnerabilities (Brown‐Elliott, Nash, & Wallace, [2012](#mbo3988-bib-0007){ref-type="ref"}; Flor, Capdevila, Martin, Gavalda, & Pahissa, [1996](#mbo3988-bib-0027){ref-type="ref"}; Henkle & Winthrop, [2015](#mbo3988-bib-0030){ref-type="ref"}; Johnston & Elwood, [2011](#mbo3988-bib-0034){ref-type="ref"}).

The complex drug treatment of *Mk* CPD exacerbates the public health challenge this pathogen presents. Costly, long‐term, multidrug courses with adverse side effects often reduce compliance and positive treatment outcomes (Brown‐Elliott et al., [2012](#mbo3988-bib-0007){ref-type="ref"}; Griffith et al., [2007](#mbo3988-bib-0029){ref-type="ref"}). A main first‐line treatment in the Unites States has been a regimen that includes three anti‐TB drugs (typically rifampin or rifabutin, ethambutol, and isoniazid) daily until the patient has at least 12 months of negative sputum cultures while on therapy (Griffith et al., [2007](#mbo3988-bib-0029){ref-type="ref"}; Philley & Griffith, [2015](#mbo3988-bib-0054){ref-type="ref"}). *Mk* isolates resistant to TB drugs have been reported (Brown‐Elliott et al., [2012](#mbo3988-bib-0007){ref-type="ref"}; Lyons et al., [2014](#mbo3988-bib-0045){ref-type="ref"}; Wang et al., [2010](#mbo3988-bib-0075){ref-type="ref"}; Wu et al., [2009](#mbo3988-bib-0079){ref-type="ref"}; Yamada et al., [1997](#mbo3988-bib-0080){ref-type="ref"}). In particular, resistance to rifampin, a drug which has a key role in the multidrug treatment of *Mk* infections, correlates with higher rates of treatment failure and relapse (Brown‐Elliott et al., [2012](#mbo3988-bib-0007){ref-type="ref"}; Griffith et al., [2007](#mbo3988-bib-0029){ref-type="ref"}; Wu et al., [2009](#mbo3988-bib-0079){ref-type="ref"}). For patients with rifampin‐resistant infections, a usual guideline is a regimen based on in vitro‐determined isolate susceptibilities to secondary agents (e.g., fluoroquinolones, tetracyclines, amikacin, linezolid, trimethoprim‐sulfamethoxazole, and rifabutin) and including at least three drugs (Griffith et al., [2007](#mbo3988-bib-0029){ref-type="ref"}; Philley & Griffith, [2015](#mbo3988-bib-0054){ref-type="ref"}).

Despite the burden of *Mk* infections, the biology of this pathogen remains poorly explored. Encouragingly, the completion of the *Mk* (subtype 1 strain) genome sequence was recently reported (Wang et al., [2015](#mbo3988-bib-0076){ref-type="ref"}), and various aspects of *Mk* biology have been inferred by bioinformatics and extrapolation from insights gained for *Mtb* (Veyrier et al., [2009](#mbo3988-bib-0074){ref-type="ref"}; Wang et al., [2015](#mbo3988-bib-0076){ref-type="ref"}). However, the 6.57 Mb of genetic material carried by *Mk* represents 2.16 Mb more than that present in *Mtb* (Cole et al., [1998](#mbo3988-bib-0012){ref-type="ref"}), and thus in silico approaches do not provide a full picture and may even lead to flawed conclusions. In all, it is clear that experimentation focused on *Mk* is needed to deepen our knowledge of its biology, further understand its ability to cause disease, and illuminate paths to better therapeutics. In particular, the scarcity of gene function studies and the lack of defined mutants are major barriers to progress in the field. In fact, to our knowledge, there are only four reported *Mk* gene function studies (Klein, Brown, & French, [2001](#mbo3988-bib-0037){ref-type="ref"}; Nataraj et al., [2015](#mbo3988-bib-0052){ref-type="ref"}; Onwueme, Vos, Zurita, Soll, & Quadri, [2005](#mbo3988-bib-0053){ref-type="ref"}; Sun & Zhang, [1999](#mbo3988-bib-0067){ref-type="ref"}). Moreover, no transposon (Tn) mutagenesis tool has been validated for use in *Mk*, a situation limiting the repertoire of genetic approaches to accelerate gene function dissection in this pathogen.

In this study, we explored the use of genome‐wide Tn mutagenesis‐based approaches to interrogate gene function in *Mk*. We provide proof‐of‐principle for the application of these approaches to *Mk* by using them to (a) link a conserved small RNA (sRNA) gene to colony morphology and biofilm formation and to (b) identify ≈12,000 Tn insertions that do not impede colony outgrowth. Lastly, we present the first demonstration of the susceptibility of *Galleria mellonella* (GM) larvae to *Mk*, thus setting the stage for further exploration of the GM infection model system to study this opportunistic pathogen.

2. MATERIALS AND METHODS {#mbo3988-sec-0002}
========================

2.1. Routine culturing conditions, molecular biology techniques, and reagents {#mbo3988-sec-0003}
-----------------------------------------------------------------------------

Mycobacteria were cultured under standard conditions in Middlebrook 7H9, 7H10, or 7H11 media (Difco, Becton‐Dickinson and Co.) supplemented as reported (Chavadi, Edupuganti, et al., [2011](#mbo3988-bib-0010){ref-type="ref"}; Chavadi, Stirrett, et al., [2011](#mbo3988-bib-0011){ref-type="ref"}). *Mk* cultures were agitated at 170 rpm with a few sterile glass beads (3 mm diameter) to reduce aggregation. *Mk* growth curve experiments were carried out using a 96‐well plate‐based growth assay we reported previously (Chavadi, Edupuganti, et al., [2011](#mbo3988-bib-0010){ref-type="ref"}), except that the plates were incubated at 37°C. Where appropriate, kanamycin (Km, 30 µg/ml) and/or hygromycin (Hyg, 150 µg/ml) were added to the Middlebrook media. Culturing of *Escherichia coli* strains was done under standard conditions in Luria--Bertani broth and agar media (Sambrook & Russell, [2001](#mbo3988-bib-0063){ref-type="ref"}). When required, ampicillin (Amp, 100 µg/ml), Km (30--50 µg/ml), Hyg (150 µg/ml), and/or 5‐bromo‐4‐chloro‐3‐indolyl‐β‐d‐galactopyranoside (X‐Gal, 56 μg/ml) were added to the Luria--Bertani media. DNA manipulations were carried out using established protocols and *E. coli* as the primary cloning host (Sambrook & Russell, [2001](#mbo3988-bib-0063){ref-type="ref"}). PCR‐generated DNA fragments used in plasmid constructions were sequenced by the Sanger method to verify fidelity (Genewiz, Inc.). Sequence alignments were carried out using DNASTAR\'s Lasergene sequence analysis software (DNASTAR, Inc.). Predictions of sRNA structures and minimum free energies were obtained with mFold software using default parameters (Zuker, [2003](#mbo3988-bib-0083){ref-type="ref"}). Isolation of *Mk* genomic DNA, plasmid electroporation into *Mk*, and selection of *Mk* transformants were carried out following standard methodologies (Chavadi, Edupuganti, et al., [2011](#mbo3988-bib-0010){ref-type="ref"}; Chavadi, Stirrett, et al., [2011](#mbo3988-bib-0011){ref-type="ref"}). Unless otherwise indicated, reagents were purchased from Sigma‐Aldrich Inc., Thermo Fisher Scientific Inc., New England Biolabs Inc., Qiagen LLC , or VWR International, LLC. The strains and oligonucleotides used in this study are listed in Tables [A1](#mbo3988-tbl-0002){ref-type="table"} and [A2](#mbo3988-tbl-0003){ref-type="table"}, respectively (Appendix [1](#mbo3988-app-0001){ref-type="app"}).

2.2. Phage stock preparation, transductions, and transposon mutant selection {#mbo3988-sec-0004}
----------------------------------------------------------------------------

High‐titer stocks (≈10^11^ PFU/ml) of the ϕMycoMarT7 phage were generated and titrated using *Mycobacterium smegmatis* (*Msm*) as reported (Siegrist & Rubin, [2009](#mbo3988-bib-0066){ref-type="ref"}). For *Mk* transductions, bacteria from actively growing cultures were harvested by centrifugation, washed twice with 1 culture volume of phage buffer (PB: supplemented 7H9 medium lacking Tween‐80), and concentrated 10 times in PB. *Mk* suspension aliquots were combined with phage stock aliquots to obtain transduction mixtures with desired PFU‐to‐CFU multiplicity of infection (MOI) values. MOIs of 0.3:1 and 1:1 (average) were used in the transductions for generation of the mutant libraries used in the genetic screen and the transposon insertion sequencing experiment, respectively. Mock transduction controls were routinely prepared by adding equivalent volumes of PB to the cell suspensions. Transduction mixtures and mock controls were incubated at 37°C without shaking for 4 hr. After incubation, aliquots of transduction mixtures and mock controls were used to enumerate Km resistant (Km^R^) CFU and total CFU on agar plates with and without Km, respectively. The remainder of each transduction mixture was made 10% glycerol, aliquoted, and stored at −80°C until use.

2.3. Arrayed library preparation {#mbo3988-sec-0005}
--------------------------------

Transduction mixtures were plated on supplemented Middlebrook 7H10 medium with Km to obtain 100 Tn mutant colonies per plate. The plates were incubated at 37°C for three weeks for Km^R^ colony growth. The Km^R^ colonies were picked and individually arrayed in 96‐well plates (Falcon, Corning) preloaded with supplemented Middlebrook 7H9 medium with Km (200 µl/well). The 96‐well plates were incubated at 37°C with orbital shaking (170 rpm) under a humidified atmosphere for 8 days to grow the microcultures. After incubation, the microcultures were homogenized with a multichannel pipette and replicate inoculated (1.5 µl transfer) with a 96‐pin inoculator (Clonemaster™; Immusine Laboratories, Inc.) into new 96‐well culture plates preloaded with fresh medium. The inoculated plates were then incubated as described above for microculture growth. After incubation, the microcultures were made 4% glycerol and the 96‐well library plates were sealed with sterile adhesive foil film sheets and stored at −80°C until use.

2.4. Morphology screen {#mbo3988-sec-0006}
----------------------

The microcultures in the 96‐well library plates were defrosted and homogenized with a multichannel pipette. The microcultures of each library plate were then subcultured into a pair of 96‐well plates (5 µl inoculum into a well preloaded with 195 µl of medium) using an every‐other‐well redistribution pattern. The inoculated 96‐well plates were incubated to grow the microcultures to late‐log phase. Following the incubation, the microcultures were homogenized as above, and 1.5 µl of each microculture was spotted onto supplemented 7H10 plates using a 96‐pin inoculator. The inoculated screen plates were incubated at 37°C until most macrocolonies reached 0.5--1.0 cm in diameter (≈18 days). After incubation, the screen plates were scrutinized for macrocolonies with mutant phenotypes by naked eye and using an Olympus SZX7 stereo microscope (Olympus Corp.).

2.5. Southern blot hybridization analysis {#mbo3988-sec-0007}
-----------------------------------------

Samples of genomic DNA (0.5--1.0 µg) digested with SacII (an enzyme that does not cut within the Tn) were separated alongside a prestained DNA molecular weight marker (F. Hoffmann‐La Roche, Ltd.) by electrophoresis in a 0.7% agarose gel. After electrophoresis, the DNA on the gel was denatured and transferred onto a nylon membrane (Amersham Hybond N+; GE Healthcare Life Sciences) as reported (Quadri, Sailer, Roy, Vederas, & Stiles, [1994](#mbo3988-bib-0057){ref-type="ref"}). The Tn‐specific 512‐bp DIG‐labeled DNA hybridization probe was generated by PCR amplification using primers GG1 and GG2 and a PCR DIG‐labeled probe synthesis kit (F. Hoffmann‐La Roche, Ltd.) according to manufacturer\'s instructions. The probe was used for the hybridization analysis following reported protocols (Quadri et al., [1994](#mbo3988-bib-0057){ref-type="ref"}; Sambrook & Russell, [2001](#mbo3988-bib-0063){ref-type="ref"}) and visualized by chromogenic detection using a DIG‐labeled DNA detection kit (F. Hoffmann‐La Roche, Ltd.) according to the DIG Application manual (F. Hoffmann‐La Roche, Ltd.).

2.6. Identification of the transposon insertion site in *Mycobacterium kansasii* 13D6 {#mbo3988-sec-0008}
-------------------------------------------------------------------------------------

Cloning of the Tn‐containing genomic fragment and Tn‐genome junction sequencing were carried out as reported (Siegrist & Rubin, [2009](#mbo3988-bib-0066){ref-type="ref"}). Briefly, genomic DNA digested with SacII was self‐ligated and transformed into *E. coli* DH5α λpir for rescue cloning of Tn‐containing genomic fragments. The cloned plasmids were purified, and the Tn‐genome junctions were sequenced using primers CB2 and CB2b. The genomic sequences identified were mapped onto the *Mk* ATCC 12478 genome (chromosome: GenBank NC_022663.1; plasmid pMK12478: GenBank NC_022654.1).

2.7. Construction of plasmids pML‐B11 and pML1335^Δ^ ^*xylE*^ {#mbo3988-sec-0009}
-------------------------------------------------------------

To generate pML‐B11, vector pML1335 (Huff, Czyz, Landick, & Niederweis, [2010](#mbo3988-bib-0033){ref-type="ref"}) was digested with BspHI and NotI to excise the *xylE* marker segment. The resulting linearized vector backbone was ligated to a BspHI‐NotI fragment encompassing the *Mk B11* gene along with its adjacent extragenic regions (chromosomal coordinates 2809862--2810381, 520 bp). The fragment was generated by PCR amplification from genomic DNA using primers CB3 and CB7, cloned into pCR2.1‐TOPO (TOPO TA cloning kit; Invitrogen), sequenced for fidelity verification, and then subcloned into the pML1335 backbone as noted above to create pML‐B11. The sequence of *B11* determined for the ATCC^®^ 12478™ strain used in this study was found to have a hepta‐C string instead of the hexa‐C string in the annotated chromosome (GenBank: NC_022663.1) that maps to the loop of the middle stem‐loop of the sRNA. Plasmid pML1335^Δ^ ^*xylE*^ (empty vector control) was generated by removal of the *xylE* marker segment of pML1335 and subsequent vector backbone religation.

2.8. RNA isolation {#mbo3988-sec-0010}
------------------

Pellets containing 1--5 × 10^7^ CFU of *Mk* grown in supplemented Middlebrook 7H9 medium to log phase or scrapings of equivalent mass taken from macrocolonies grown at 37°C for 23 days on supplemented Middlebrook 7H10 plates were resuspended in 1 ml TRIzol™ reagent (Invitrogen™). The resuspended cells were lysed with zirconia/silica beads (Bio Spec Products Inc.) in a bead‐beater homogenizer (Mini‐BeadBeater 16, Bio Spec Products Inc.) using two bead‐beating cycles of 50 s each separated by a 10‐min chilling step on ice. The lysates were spun (22,000 *g*, 2 min, 4°C) to pellet beads and cellular debris. The supernatants were transferred to siliconized microcentrifuge tubes, combined with 300 µl of chloroform:isoamyl alcohol (24:1), shaken vigorously for 15 s, and incubated at room temperature for 3 min. After incubation, the samples were centrifuged (12,000 *g*, 15 min, 4°C), and the RNA was isolated from the supernatant using PureLink™ RNA Mini and miRNA Isolation Kits (Invitrogen™) following the manufacturer\'s instructions.

2.9. Northern blot analysis {#mbo3988-sec-0011}
---------------------------

Total RNA (1 µg, originated from 2 × 10^6^ CFU) was separated on a 6% denaturing polyacrylamide gel (Novex precast 6% TBE‐Urea polyacrylamide gel, Invitrogen™) run in a XCell SureLock™ Mini‐Cell (Invitrogen™) according to manufacturer\'s protocols. Prestained molecular weight markers (DynaMarker DM270; BioDynamics Laboratory Inc.) were separated alongside *Mk* total RNA and the 100‐bp hybridization probe fragment (see below), which was used as reference for maker size calibration. After electrophoresis, the gel was electroblotted onto a nylon membrane (Amersham Hybond N+; GE Healthcare Life Sciences) using a XCell SureLock™ Mini‐Cell Blot Module (Invitrogen™) in the XCell SureLock™ Mini‐Cell according to manufacturer\'s instructions and subsequently baked for 2 hr at 80°C. An *Mk B11*‐specific DIG‐labeled hybridization probe (100 bp; genome coordinates 2810109--2810208) was generated by PCR amplification using primers CB9c3 and CB8c and a PCR DIG‐labeled probe synthesis kit (F. Hoffmann‐La Roche, Ltd.) according to manufacturer\'s instructions. The probe was used for the hybridization analysis following reported protocols (Quadri et al., [1994](#mbo3988-bib-0057){ref-type="ref"}; Sambrook & Russell, [2001](#mbo3988-bib-0063){ref-type="ref"}) and visualized by chromogenic detection using a DIG‐labeled nucleic acid detection kit (F. Hoffmann‐La Roche, Ltd.) according to the DIG Application manual (F. Hoffmann‐La Roche, Ltd.).

2.10. RT‐qPCR analysis {#mbo3988-sec-0012}
----------------------

The experiments were done using transcript target‐specific primer pairs (Table [A2](#mbo3988-tbl-0003){ref-type="table"} in Appendix [1](#mbo3988-app-0001){ref-type="app"}) and the QuantiNova^®^ SYBR^®^ Green RT‐PCR Kit as recommended by the manufacturer (Qiagen, LLC ). All primer pairs were optimized to have \>90% amplification efficiency (as judged by standard curves generated from genomic DNA) and to produce a unique amplicon (as judged by melt curve analysis) of the expected size (as judged by agarose gel electrophoresis). RNA samples used for RT‐qPCR were DNase‐treated and verified to be free of DNA contamination by PCR. One‐step RT‐qPCR reactions (10 µl, 30 pg of RNA template) were run in a Rotor‐Gene Q light cycler (Qiagen, LLC). Two‐step PCR cycling was performed as follows: 95°C for 5 s and 60°C for 10 s for 40 cycles. For each transcript target, the threshold cycle (*C* ~t~) was normalized to the *C* ~t~ of the standard mycobacterial internal calibrator *sigA* transcript to generate transcript relative abundance data as reported (Dubnau, Fontan, Manganelli, Soares‐Appel, & Smith, [2002](#mbo3988-bib-0022){ref-type="ref"}; Livak & Schmittgen, [2001](#mbo3988-bib-0043){ref-type="ref"}).

2.11. Biofilm formation {#mbo3988-sec-0013}
-----------------------

The biofilm formation assay was carried out using the MBEC™ device (Innovotech Inc.) and a protocol comparable to one we recently reported (Mohandas et al., [2016](#mbo3988-bib-0051){ref-type="ref"}). Briefly, *Mk* cells from actively growing cultures were harvested by centrifugation and resuspended to an OD~600~ of 0.1 in Middlebrook 7H9 lacking ADN supplementation (Chavadi, Stirrett, et al., [2011](#mbo3988-bib-0011){ref-type="ref"}) and Tween‐80. The cell suspensions were loaded (150 µl/well) into the 96‐well plates, and the plates were incubated with 100 rpm agitation at 37°C for 6 weeks under a humidified atmosphere. After incubation, *Mk* culture‐exposed pegs and sterile broth‐exposed control pegs were washed twice with distilled water, briefly dried at room temperature, stained for 15 min with 0.5% crystal violet (CV), rinsed thrice with distilled water, and dried overnight. The CV on the pegs was then extracted in 95% ethanol and quantified spectrophotometrically at 595 nm using a DTX 880 multimode detector microplate reader (Beckman Coulter, Inc.).

2.12. *Galleria mellonella* larva killing assay {#mbo3988-sec-0014}
-----------------------------------------------

The assay was carried out using an infectious dose and methodologies comparable to those recently reported for other slow‐growing mycobacteria (Li et al., [2018](#mbo3988-bib-0042){ref-type="ref"}). Larvae in the sixth instar stage were purchased from Timberline Fisheries, Corp. (Marion, IL) and used the day of delivery. Only larvae displaying healthy movement, no melanization signs, and 150--250 mg body weight were used in the experiments. Larvae were restrained for injection as reported (Dalton, Uy, Swift, & Wiles, [2017](#mbo3988-bib-0014){ref-type="ref"}), and injections were given into the last left pro‐leg using a 22 s ga beveled stainless steel needle affixed to a 50‐µl Hamilton syringe. For each experiment, groups of 15 larvae were injected with 10 µl of either sterile phosphate‐buffered saline \[PBS (Li et al., [2018](#mbo3988-bib-0042){ref-type="ref"})\] or PBS carrying 1 × 10^7^ CFU, or not injected. Each larval group was placed in a paper‐lined 10‐cm petri dish, and the dishes were incubated in the dark at 37°C or 25°C and observed daily for larva survival. Larvae were considered dead when no movement was elicited upon physical stimulation. Kaplan--Meier curves were used to plot survival data, and the Log‐rank (Mantel‐Cox) test embedded in Prism v6.01 (GraphPad Software, Inc.) was used for curve comparisons.

2.13. Transposon insertion sequencing experiment {#mbo3988-sec-0015}
------------------------------------------------

Colonies from a library of ≈14,700 Tn mutants were scraped from supplemented 7H11 plates, and genomic DNA was isolated from the mutant pool as reported (Chavadi, Stirrett, et al., [2011](#mbo3988-bib-0011){ref-type="ref"}). A modified TraDIS‐type method (Fan et al., [2018](#mbo3988-bib-0026){ref-type="ref"}; Langridge et al., [2009](#mbo3988-bib-0040){ref-type="ref"}) customized for the *Himar1*‐based Tn in ϕMycoMarT7 was used to identify the insertion sites in the genomic DNA library pool. Briefly, genomic DNA was fragmented to a ≈350‐bp average length and adaptor sequences were ligated to each end of the fragments using the KAPA HyperPlus Kit (Kapa Biosystems, Inc.) as recommended by the manufacturer. Two rounds of optimized PCR reactions (PCR‐1 and PCR‐2) were performed to enrich for Tn‐genomic DNA junction fragments and make the final PCR product suitable for Illumina sequencing. PCR‐1 was done with a Tn‐specific primer (CB1) and an adapter‐specific primer (IS5) for Tn‐genome junction enrichment. PCR‐2 (hemi‐nested) was run with the adapter‐specific primer IS5 and a Tn‐specific primer adding the sequences needed for Illumina sequencing and barcoding of each sample (primers CB25.3_R or CB44.3_R). (See Appendix [3](#mbo3988-app-0001){ref-type="app"} ) The generated fragment libraries were sequenced on an Illumina NextSeq 500 System using a NextSeq500/550 Mid Output Kit (150 cycles; 2 × 75 cycles; paired‐end reads; Illumina Inc.). Custom primers were spiked to initiate the index read (primer barcodeseq) and read two sequencing (primer SP2). Raw sequencing read data were processed as follows. (a) Duplicate reads (same sequences for paired‐end reads, considered PCR siblings) were compressed into a single representative read. (b) Reads were filtered further based on the presence of the terminal 5‐bp Tn sequence (TGTTA) adjacent to the Tn primer (CB25.3_R or CB44.3_R). (c) The primer sequences were trimmed. (d) Each filtered and trimmed read was mapped onto the *Mk* chromosome (GenBank: NC_022663.1) and plasmid pMK12478 (GenBank: NC_022654.1) sequences using BLAST (<https://blast.ncbi.nlm.nih.gov/BLAST>).

3. RESULTS AND DISCUSSION {#mbo3988-sec-0016}
=========================

3.1. Evaluation of the ϕMycoMarT7 transposon mutagenesis system in *Mycobacterium kansasii* {#mbo3988-sec-0017}
-------------------------------------------------------------------------------------------

The ϕMycoMarT7 phagemid system has been the most successful Tn mutagenesis approach for mycobacteria thus far (Sassetti, Boyd, & Rubin, [2001](#mbo3988-bib-0065){ref-type="ref"}). The system relies on specialized transduction by a temperature‐sensitive mycobacteriophage to deliver a *Himar1* derivative Tn. The Tn inserts randomly at TA dinucleotide sites via a cut‐and‐paste mechanism dependent on a transposase encoded outside the Tn in ϕMycoMarT7. In susceptible hosts, the ϕMycoMarT7 phage typically defaults to a lytic cycle at the permissive temperature (30°C), but it does not replicate and becomes an effective Tn delivery suicide vector at the nonpermissive temperature (37°C). The system has been demonstrated to be functional in a few *Mycobacterium* spp. (*Mtb*, *Msm*, *M. bovis* BCG, *M. avium* subsp. *paratuberculosis*, *M. marinum*, and *M. fortuitum*) (Driessen et al., [2010](#mbo3988-bib-0021){ref-type="ref"}; Sassetti et al., [2001](#mbo3988-bib-0065){ref-type="ref"}; Wang, Pritchard, Kreitmann, Montpetit, & Behr, [2014](#mbo3988-bib-0077){ref-type="ref"}). However, it is not expected to work in all *Mycobacterium* spp. due to phage host range, Tn functionality, or other limitations (Bardarov et al., [1997](#mbo3988-bib-0005){ref-type="ref"}; Rybniker, Kramme, & Small, [2006](#mbo3988-bib-0062){ref-type="ref"}). Ultimately, the functionality of the system in any given *Mycobacterium* sp. needs to be experimentally determined.

Due to the advantages of the ϕMycoMarT7 system, we set out to evaluate its performance in *Mk*. To this end, we first assessed the ability of the phage to produce plaques on *Mk* lawns at the permissive and nonpermissive temperatures. As a control, we carried out the equivalent experiment using lawns of *Msm*, the standard host for ϕMycoMarT7 phage propagation and titration. These experiments revealed that the phage was able to produce plaques on *Mk* lawns only at the permissive temperature (Figure [1](#mbo3988-fig-0001){ref-type="fig"}a) and that the plaque formation efficiency was ≈800‐fold lower in the pathogen than in *Msm* (Figure [1](#mbo3988-fig-0001){ref-type="fig"}b). The latter finding suggests that either the infection step or the lytic cycle, or both, is less efficient in *Mk*. Overall, these results demonstrate that the ϕMycoMarT7 phage infects *Mk* and its temperature sensitivity trait is maintained in this pathogen.

![Functionality of the ϕMycoMarT7‐based transposon mutagenesis system in *Mycobacterium kansasii*. (a) Images showing the plaque formation capacity of the ϕMycoMarT7 phage on lawns of *Mk* and *Msm* at the permissive (30°C) and nonpermissive (37°C) temperatures. The numbers to the left of the image represent a 10‐fold dilution series of the phage stock. UD, undiluted phage stock. (b) Comparison of plaque formation efficiency on lawns of *Mk* and *Msm* at the permissive temperature. The data represent mean ± *SE* of at least two PFU titrations. (c) Effect of the multiplicity of infection (MOI) used in the transduction mixture on the efficiency of generation of *Mk* Tn mutants](MBO3-9-e988-g001){#mbo3988-fig-0001}

We next investigated whether ϕMycoMarT7 could deliver the Tn to *Mk* at the nonpermissive temperature to give rise to Tn mutants. We carried out *Mk* transductions and followed each of them with selective outgrowth and enumeration of Km^R^ colonies. We also carried out mock transduction control experiments (phage omitted) to determine the frequency of spontaneous Km^R^ mutants under our experimental conditions. In all, we found that the number of Tn mutants increased with the MOI used in the transduction mixture (Figure [1](#mbo3988-fig-0001){ref-type="fig"}c) and observed no meaningful frequency of spontaneous Km^R^ colonies (less than 1 in 10^6^ CFU; not shown). Lastly, the results of the transposon insertion sequencing (TIS) experiment described below confirmed that the TA site specificity of the Tn is preserved in *Mk*. In all, our results demonstrate that the ϕMycoMarT7‐based Tn mutagenesis system is fully functional in *Mk*.

3.2. A *Mycobacterium kansasii* transposon mutant library screen links a conserved sRNA gene of unknown function to colony morphology {#mbo3988-sec-0018}
-------------------------------------------------------------------------------------------------------------------------------------

The realization that the ϕMycoMarT7 system is functional in *Mk* opens the possibility to explore its use in forward genetic screens to unveil genotype‐phenotype associations and dissect gene function. To pilot this concept, we carried out a small screen for macrocolony morphology mutants. We note that the term "macrocolony" used herein refers to the growth arising from spot inoculation (multi‐CFU seeding) from a liquid culture onto solid growth media, a colonial growth often considered a biofilm community (e.g., Chapelais‐Baron et al., [2018](#mbo3988-bib-0009){ref-type="ref"}; Kempes, Okegbe, Mears‐Clarke, Follows, & Dietrich, [2014](#mbo3988-bib-0035){ref-type="ref"}).

We selected a macrocolony morphology screen for our concept exploration because we hypothesized that it might lead to identification of mutants with insertions in genes involved in defining cell envelope surface properties with an impact on biofilm formation capacity, a trait linked to the public health problem associated with *Mk*. Environmental *Mk* biofilms are considered recalcitrant pathogen reservoirs, and biofilm formation in the host is thought to contribute to the intractability of mycobacterial infections (Aldridge, Keren, & Fortune, [2014](#mbo3988-bib-0001){ref-type="ref"}; Chakraborty & Kumar, [2019](#mbo3988-bib-0008){ref-type="ref"}). Thus, identification of genes involved in biofilm formation will lead to a better understanding of *Mk* biology and illuminate potential paths to new therapeutics and strategies for pathogen reservoir eradication.

For the pilot screen, we generated a library of several hundred Tn mutants arrayed in 96‐well plates, spot‐inoculated the library onto solid growth medium plates, incubated the screen plates for macrocolony growth, and then scrutinized the plates for mutants with macrocolony abnormalities. We identified a mutant (herein referred to as 13D6) visibly distinct from the wild type (WT) (Appendix [2](#mbo3988-app-0002){ref-type="app"}, Figure [A1](#mbo3988-fig-0008){ref-type="fig"}) and selected it for further analysis. We found that the typical 13D6 macrocolony had a reduced diameter, abnormal surface topology, and a smooth and glistening appearance that contrasted the rough and dried phenotype of the WT (Figure [2](#mbo3988-fig-0002){ref-type="fig"}a). The distinct phenotype of the mutant was even more evident on streak plates (Figure [2](#mbo3988-fig-0002){ref-type="fig"}b). Single colonies of 13D6 were also reduced in size (Figure [2](#mbo3988-fig-0002){ref-type="fig"}c) and displayed an atypical surface appearance (Figure [2](#mbo3988-fig-0002){ref-type="fig"}d) compared to WT. Notably, the mutant displayed cell shape and planktonic growth comparable to that of the parental strain (Appendix [2](#mbo3988-app-0002){ref-type="app"}, Figure [A2](#mbo3988-fig-0009){ref-type="fig"}).

![Morphology phenotypes of *Mycobacterium kansasii* strains. (a) Representative spot inoculation‐derived macrocolonies showing morphological features. Scale bar = 2 mm. (b) Plates with bacterial streaks (top; scale bar = 1 cm) and enlargements (bottom; scale bar = 2 mm) of the boxed sections showing surface topology and appearance features. (c) Plates with isolated single colonies. Scale bar = 1 cm. Colony diameter (cm) information is presented below each plate. The values shown represent mean ± *SE*. \*Student\'s *t* test *p* values \<.05; ns, no significant difference (*p* ≥ .05). (d) Representative single colonies showing morphology detail. Scale bar = 2 mm. WT, wt‐v; M, 13D6‐v; C, 13D6‐c](MBO3-9-e988-g002){#mbo3988-fig-0002}

Colony morphology is a trait influenced by multiple factors. It is well documented that mycobacterial mutants with abnormal colony morphology often carry mutations in genes implicated in metabolism of complex glycolipids of the outer membrane‐like structure (i.e., the mycomembrane) of the mycobacterial cell envelope, (Ren et al., [2007](#mbo3988-bib-0058){ref-type="ref"}; Tatham et al., [2012](#mbo3988-bib-0069){ref-type="ref"}; Yu et al., [2012](#mbo3988-bib-0081){ref-type="ref"}). In particular, alterations in the content of mycomembrane glycolipids known as lipooligosaccharides (LOS) have been linked occasionally to smooth‐rough morphotype changes in *Mk* (Belisle & Brennan, [1989](#mbo3988-bib-0006){ref-type="ref"}; Nataraj et al., [2015](#mbo3988-bib-0052){ref-type="ref"}). Thus, it is tempting to speculate that the abnormal (macro)colony appearance of the 13D6 mutant suggests that the Tn insertion led to changes in mycomembrane composition and/or structure.

We verified that 13D6 had a single Tn insertion (Appendix [A2](#mbo3988-app-0002){ref-type="app"}, Figure [A3](#mbo3988-fig-0010){ref-type="fig"}) and identified the insertion site. We found that the Tn had inserted 6 bp upstream of what we propose is a nonannotated sRNA gene orthologous to a nonessential *Mtb* sRNA gene of unknown function named *B11* (a.k.a. *ncRv13660c*) (Arnvig, Cortes, & Young, [2014](#mbo3988-bib-0002){ref-type="ref"}; Arnvig & Young, [2009](#mbo3988-bib-0003){ref-type="ref"}; DeJesus et al., [2017](#mbo3988-bib-0017){ref-type="ref"}) (Figure [3](#mbo3988-fig-0003){ref-type="fig"}a). The two orthologs have high sequence identity (Figure [3](#mbo3988-fig-0003){ref-type="fig"}b), and their sRNA products have essentially the same predicted secondary structure (Figure [3](#mbo3988-fig-0003){ref-type="fig"}c). Following the new nomenclature guidelines for naming mycobacterial noncoding sRNAs (Lamichhane, Arnvig, & McDonough, [2013](#mbo3988-bib-0039){ref-type="ref"}), we named the predicted *Mk* sRNA gene *ncMKAN_RS112130c* (herein referred to as *Mk B11* for simplicity). Our cross‐species genome sequence similarity analysis revealed that the *B11* gene locus is highly conserved in the *Mycobacterium* genus (Appendix [2](#mbo3988-app-0002){ref-type="app"}, Figure [A4](#mbo3988-fig-0004){ref-type="fig"}a) and in many representative members of other genera of *Actinobacteria* (not shown). These findings are consistent with reported analyses (DiChiara et al., [2010](#mbo3988-bib-0020){ref-type="ref"}; Mai et al., [2019](#mbo3988-bib-0046){ref-type="ref"}; Weinberg et al., [2007](#mbo3988-bib-0078){ref-type="ref"}). The conservation of this gene suggests that its sRNA product has a critical function in the biology of *Actinobacteria*.

![*Mycobacterium kansasii* 13D6 has a transposon insertion located 6 bp upstream of an sRNA gene (*Mk B11*) orthologous to the *Mycobacterium tuberculosis* sRNA gene *B11*. (a) Outline depicting the Tn (*Escherichia coli* replication origin oriR6k and *aph* Km^R^ marker are represented), the location of the TA insertion site (chromosomal coordinates are shown), and the conservation of genetic features nearby the insertion site in the *Mk* chromosome (NC_022663.1) and the orthologous segment in the *Mtb* chromosome (NC_000962.3). Chromosomal coordinates of the segments are indicated. The coordinates of the chromosomal fragment included in the complementation plasmid pML‐B11 are marked by an asterisk (\*). Nucleotide (nt) and amino acid (aa) identity between specific sections of the segments is provided. (b) Sequence alignment of *Mk* and *Mtb B11* loci. The boxed sequences correspond to the annotated *Mtb B11* gene. The location of the Tn (inverted triangle) and putative promoter and terminator sequences are depicted. (c) Predicted secondary structures for the sRNA products of the *B11* genes. The minimum free energy associated with each structure is shown](MBO3-9-e988-g003){#mbo3988-fig-0003}

![Northern blot analysis of *Mycobacterium kansasii* B11 sRNA in *M. kansasii* strains. (a) Representative northern blot demonstrating the presence of B11 sRNA in the WT strain (wt‐v, lane WT) and complemented strain (13D6‐c, lane C) and its absence in the mutant strain (13D6‐v, lane M). Lane MW, molecular weight markers; lane P, B11 probe fragment (100 bp). (b) Northern blot‐based comparison of B11 expression in the WT (WT) and complemented (C) strains. The bands on the blot were quantified by densitometry analysis using ImageJ software (NIH, available in the public domain). The data represent mean ± *SE* of quantifications from three northern blots. \*Student\'s *t* test *p* values \<.0001](MBO3-9-e988-g004){#mbo3988-fig-0004}

Based on the position of the Tn in the 13D6 mutant, we hypothesized that the insertion might have abolished *B11* transcription by separating the gene from its promoter. Consistent with this idea, the *Mk B11* 5′ flanking region contains a putative SigA‐dependent promoter (Figure [3](#mbo3988-fig-0003){ref-type="fig"}b), a feature conserved in the *Mtb B11* locus (Arnvig & Young, [2009](#mbo3988-bib-0003){ref-type="ref"}). We found the equivalent putative promoter sequence upstream of the *B11* orthologs in other *Mycobacterium* spp. (Appendix [2](#mbo3988-app-0002){ref-type="app"}, Figure [A4](#mbo3988-fig-0004){ref-type="fig"}b). To investigate the hypothesized impact of the Tn insertion in 13D6 on *B11* expression, we compared *B11* transcript levels between the 13D6 and WT strains by northern blot analysis of RNA isolated from planktonic cultures and by RT‐qPCR analysis of RNA isolated from macrocolonies and from planktonic cultures. We also assessed whether the transcript levels of the genes flanking *B11* (i.e., *MKAN_RS12130* and *MKAN_RS12135*; Figure [3](#mbo3988-fig-0003){ref-type="fig"}a) had been altered in 13D6. The northern blot analysis revealed an sRNA transcript (≈80 nt) in the expected size range in the WT strain but not in the mutant (Figure [4](#mbo3988-fig-0004){ref-type="fig"}a). In agreement with this, the RT‐qPCR analysis showed that the insertion led to reductions in transcript levels of 769‐fold and 833‐fold in macrocolony cells (Figure [5](#mbo3988-fig-0005){ref-type="fig"}a) and planktonic cells (Figure [5](#mbo3988-fig-0005){ref-type="fig"}b), respectively, relative to WT. Conversely, the insertion had no significant impact on the transcript levels of the flanking genes in either macrocolony (Figure [5](#mbo3988-fig-0005){ref-type="fig"}c) or planktonic (Figure [5](#mbo3988-fig-0005){ref-type="fig"}d) cells. Thus, we conclude that the Tn insertion essentially shut down *B11* transcription from its native promoter, and attribute the residual *B11* transcript detected in the mutant by the highly sensitive RT‐qPCR analysis to Tn‐driven trace transcription of the downstream *B11* gene, a view supported by the literature on the Tn delivered by ϕMycoMarT7 (Rubin et al., [1999](#mbo3988-bib-0060){ref-type="ref"}; Zhang et al., [2012](#mbo3988-bib-0082){ref-type="ref"}).

![RT‐qPCR expression analysis of *B11* and adjacent genes in *Mycobacterium kansasii* strains. (a) Expression of *B11* in macrocolonies. (b) Expression of *B11* in planktonic cells. (c) Expression of *B11* gene neighbors in macrocolonies. (d) Expression of *B11* gene neighbors in planktonic cells. WT, wt‐v; M, 13D6‐v; C, 13D6‐c. In‐bar values reflect fold reduction in the indicated strain relative to WT. Data represent mean ± *SE* of at least two independent experiments. Student\'s *t* test *p* values: \*\<.05; \*\*\<.01; ns, no significant difference (*p* ≥ .05)](MBO3-9-e988-g005){#mbo3988-fig-0005}

In light of these results, we hypothesized that the lack of WT levels of *B11* transcription in the 13D6 mutant led to the morphology phenotype. To test this idea, we engineered and analyzed the phenotype of a genetic complementation control strain (13D6‐c). The strain was generated using the plasmid pML‐B11 to endow 13D6 with a WT copy of the *B11* locus by plasmid integration at the mycobacteriophage L5 *attB* site of the *Mk* chromosome (coordinates 1225397--1225458; Appendix [2](#mbo3988-app-0002){ref-type="app"}, Figure [A5](#mbo3988-fig-0012){ref-type="fig"}), which we identified using the *Msm attB* site as reference sequence (Lee, Pascopella, Jacobs, & Hatfull, [1991](#mbo3988-bib-0041){ref-type="ref"}). pML‐B11 carries *B11* along with its adjacent extragenic regions (Figure [3](#mbo3988-fig-0003){ref-type="fig"}a), which were included in the cloned fragment to preserve any unrecognized cis‐acting elements that might have been required for control of *B11* transcription or *B11* transcript termination or processing. We also constructed an empty vector (pML1335^Δ^ *^xylE^*)‐carrying control of 13D6 (strain 13D6‐v) and one of the WT (strain wt‐v), and included these strains in the complementation analysis. Evaluation of the morphology phenotype of the various strains revealed that empty vector integration had no impact on the phenotype of the mutant, whereas integration of pML‐B11 led to a strong partial complementation (Figure [2](#mbo3988-fig-0002){ref-type="fig"}).

The partial complementation seen in 13D6‐c led us to assess whether the transcript level of *B11* in the strain had indeed been restored to WT levels. We found that integration of pML‐B11 in 13D6 raised the *B11* transcript level 179‐fold (to 23.30% of WT) in macrocolony cells (Figure [5](#mbo3988-fig-0005){ref-type="fig"}a) and 373‐fold (to 44.81% of WT) in planktonic cells (Figure [5](#mbo3988-fig-0005){ref-type="fig"}b) as judged by RT‐qPCR analysis. The results are in good agreement with those derived from the northern blot analysis, which indicates a *B11* transcript level recovery of 34.14% in the planktonic cells of 13D6‐c relative to WT levels (Figure [4](#mbo3988-fig-0004){ref-type="fig"}b). In light of the results of the *B11* expression analysis, we conclude that the partial complementation is likely due to incomplete restoration of *B11* transcript levels. Overall, our findings establish a previously unrecognized role of *Mk B11*, or any mycobacterial sRNA gene, in the development of (macro)colony morphology features.

3.3. Disruption of *B11* transcription leads to biofilm formation deficiency {#mbo3988-sec-0019}
----------------------------------------------------------------------------

As noted above, we theorized that our macrocolony morphology screen could lead to identification of mutants with insertions in genes involved in defining cell surface properties with an impact on biofilm formation, a trait that contributes to the pathogen\'s resilience in environmental reservoirs and in the host. Thus, we investigated the effect of the Tn insertion in 13D6 on biofilm formation using the MBEC™ device. Comparison of the WT and mutant strains in biofilm experiments revealed that only the WT formed biofilm microcolonies on the pegs of the device (Figure [6](#mbo3988-fig-0006){ref-type="fig"}a). As noted above, the strains have comparable planktonic growth (Appendix [2](#mbo3988-app-0002){ref-type="app"}, Figure [A2](#mbo3988-fig-0009){ref-type="fig"}b) and planktonic growth in MBEC™ plates were indistinguishable between both strains, ruling out the possibility that the observed biofilm formation deficiency of the mutant was due to lack of bacterial growth. The biofilm formation capacity of the *B11* locus‐complemented strain 13D6‐c was restored to a level comparable to WT (Figure [6](#mbo3988-fig-0006){ref-type="fig"}a). Biofilm quantification using a CV‐based colorimetric method (Figure [6](#mbo3988-fig-0006){ref-type="fig"}b) recapitulated the results from direct peg observation. Taken together, our results demonstrate that the biofilm formation defect of 13D6 is due to a lack of *B11* expression. To our knowledge, 13D6 is the first *Mk* biofilm deficient mutant reported, and our results provide the first example of a mycobacterial sRNA gene involved in biofilm formation.

![Biofilm formation by *Mycobacterium kansasii* strains. (a) Representative image of crystal violet‐stained MBEC™ device pegs. (b) Quantification of biofilm formation on pegs using the crystal violet‐based colorimetric assay. WT, wt‐v; M, 13D6‐v; C, 13D6‐c; ctrl, sterile medium control. Data represent mean ± *SE* of three independent experiments. \*Student\'s *t* test *p* values \<.05; ns, no significant difference (*p* ≥ .05)](MBO3-9-e988-g006){#mbo3988-fig-0006}

Overall, our findings indicate that the lack of *B11* expression in 13D6 has a pleiotropic effect that impacts (macro)colony morphology features and biofilm formation. The molecular mechanism behind this phenomenon remains to be elucidated. It is tempting to speculate, however, that the sRNA regulates *Mk* genes influencing colony morphology features and biofilm formation. Interestingly, recent studies have shown that expression of *Mtb B11* in *Msm*, which carries its native *B11* ortholog (Appendix [2](#mbo3988-app-0002){ref-type="app"}, Figure [A4](#mbo3988-fig-0004){ref-type="fig"}a), leads to reduced growth and elongated cell shape, and support a model in which the *Mtb* *B11* sRNA represses *Msm* gene expression by a mechanism requiring base‐pairing of C‐rich loops in the sRNA to G‐rich stretches in mRNA targets (Arnvig & Young, [2009](#mbo3988-bib-0003){ref-type="ref"}; Mai et al., [2019](#mbo3988-bib-0046){ref-type="ref"}). Despite this recent progress, the role of this family of sRNA orthologs in actinobacterial biology remains poorly understood and further studies to elucidate their regulatory functions are warranted.

3.4. Disruption of B11 transcription does not cause attenuation in a *Galleria mellonella* larva killing assay {#mbo3988-sec-0020}
--------------------------------------------------------------------------------------------------------------

The GM larva has emerged as a simple and economical invertebrate model host to evaluate virulence of microbial pathogens and efficacy of antimicrobial compounds (Tsai, Loh, & Proft, [2016](#mbo3988-bib-0071){ref-type="ref"}). Recent studies have validated the use of this model with mycobacteria and shown that larva lethality is species‐dependent (Entwistle & Coote, [2018](#mbo3988-bib-0024){ref-type="ref"}; Li et al., [2018](#mbo3988-bib-0042){ref-type="ref"}; Meir, Grosfeld, & Barkan, [2018](#mbo3988-bib-0048){ref-type="ref"}; Rwegasila, Mubofu, Nyandoro, Erasto, & Munissi, [2016](#mbo3988-bib-0061){ref-type="ref"}). Given the tractability of this model, we used a GM larva killing assay to provide a first comparison of the WT and 13D6 strains in an in vivo setting. We challenged GM with these strains and monitored larval survival during incubation at either 37°C or 25°C. Comparison of the survival curves of the infected groups with the uninfected controls clearly demonstrated *Mk*‐dependent killing at 37°C (Figure [7](#mbo3988-fig-0007){ref-type="fig"}a). However, we found no difference between the survival curves of the *Mk*‐infected groups. Interestingly, we found no significant *Mk*‐dependent killing at 25°C (Figure [7](#mbo3988-fig-0007){ref-type="fig"}b), a temperature much less favorable for *Mk* replication. Overall, our infection experiments revealed that the Tn‐dependent disruption of *B11* transcription in 13D6 had no substantial impact on virulence in the GM model. To our knowledge, our findings provide the first demonstration of the susceptibility of GM larva to *Mk*, thus setting the stage for further exploration of this model for *Mk* studies.

![Kaplan--Meier survival curves demonstrating temperature‐dependent killing of *Galleria mellonella* larvae by *Mycobacterium kansasii*. WT, WT strain; M, 13D6 mutant; BC, PBS buffer control; NIC, noninjected control. Statistical differences between survival curves were assessed using the Log‐rank test. *p* values: \*\*\*\<.0001; \*\*.0053; \*.0362; ns, no significant difference (*p* ≥ .05)](MBO3-9-e988-g007){#mbo3988-fig-0007}

3.5. A transposon insertion sequencing approach identifies 12,071 insertions that do not compromise *Mycobacterium kansasii* viability {#mbo3988-sec-0021}
--------------------------------------------------------------------------------------------------------------------------------------

TIS approaches are powerful tools for high‐throughput gene function studies and systems‐level analysis of microorganisms (van Opijnen & Camilli, [2013](#mbo3988-bib-0073){ref-type="ref"}). We probed the application of TIS in *Mk* using a modified TraDIS‐type method (Fan et al., [2018](#mbo3988-bib-0026){ref-type="ref"}; Langridge et al., [2009](#mbo3988-bib-0040){ref-type="ref"}) customized for the Tn of ϕMycoMarT7 to identify the insertion sites in a DNA library pool generated from a nonsaturated Tn mutant library of ≈14,700 mutant colonies. The analysis mapped a total of 12,071 different TA insertion sites (Table [1](#mbo3988-tbl-0001){ref-type="table"}, Figure [A6](#mbo3988-fig-0013){ref-type="fig"} in Appendix [2](#mbo3988-app-0002){ref-type="app"}), indicating that none of these insertions disrupted essential functions required for colony outgrowth under our experimental conditions. Of the 12,071 insertions, 9,885 were intragenic, impacting 3,474 (62%) genes of the chromosome (Table S1, available at <https://doi.org/10.5281/zenodo.3561175>) and 112 (74%) genes of the plasmid pMK12478 (Table S2, available at <https://doi.org/10.5281/zenodo.3561175>). The TA sites hit by the Tn in the chromosome and in pMK12478 represent 12% and 17% of the total TA sites in each amplicon, respectively (Table [1](#mbo3988-tbl-0001){ref-type="table"}). The chromosome and pMK12478 have a comparable percent of coding bp (87% and 84%, respectively), and the same average frequencies of intragenic TA sites (1 TA/71 bp) and intergenic TA sites (1 TA/43 bp). Notably, however, while the percent of intergenic TA sites hit for the two amplicons relative to the respective total intergenic TA sites is essentially the same (11%--12%), the percent of intragenic TA sites hit relative to the amplicon\'s total intragenic TA sites is considerably depressed in the chromosome (12%) compared to that of the plasmid (18%). Since insertions disrupting essential functions required for colony outgrowth are not expected to be represented in the mutant library, the observed bias against chromosomal intragenic insertions is probably a reflection of the presence of essential genes in the chromosome. We note that the nonsaturated nature of the library analyzed (Table [1](#mbo3988-tbl-0001){ref-type="table"}, Figure [A6](#mbo3988-fig-0013){ref-type="fig"} in Appendix [2](#mbo3988-app-0002){ref-type="app"}) precludes the statistical analysis of insertion distribution along replicons and locus‐dependent transposition biases often associated with saturation Tn mutagenesis approaches used in gene essentiality analysis (DeJesus, Ambadipudi, Baker, Sassetti, & Ioerger, [2015](#mbo3988-bib-0016){ref-type="ref"}; DeJesus et al., [2017](#mbo3988-bib-0017){ref-type="ref"}; DeJesus & Ioerger, [2013](#mbo3988-bib-0018){ref-type="ref"}; DeJesus et al., [2013](#mbo3988-bib-0019){ref-type="ref"}; Griffin et al., [2011](#mbo3988-bib-0028){ref-type="ref"}; Long et al., [2015](#mbo3988-bib-0044){ref-type="ref"}). Nevertheless, in all, our results expand our knowledge of *Mk* gene function, provide proof‐of‐principle for the use of a ϕMycoMarT7‐based TIS approach in *Mk*, and set a methodological framework for coupling saturating Tn mutagenesis and TIS for genome‐scale gene function analysis and systems‐level studies in this mycobacterial pathogen.

###### 

Summary of mapped transposon insertion sites in the *Mycobacterium kansasii* chromosome and plasmid

                                                                  Chromosome        Plasmid
  --------------------------------------------------------------- ----------------- ----------------
  Total TA sites hit                                              11,696            375
  Total TA sites hit relative to total TA sites                   12% (of 97,702)   17% (of 2,251)
  Intragenic TA sites hit                                         9,573             312
  Intragenic TA sites hit relative to total TA sites hit          82%               83%
  Intragenic TA sites hit relative to total intragenic TA sites   12% (of 78,383)   18% (of 1,723)
  Intergenic TA sites hit                                         2,123             63
  Intergenic TA sites hit relative to total TA sites hit          18%               17%
  Intergenic TA sites hit relative to total intergenic TA sites   11% (of 19,319)   12% (of 528)
  Total genes hit                                                 3,474             113
  Genes hit relative to total annotated genes                     62%               74%
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4. CONCLUSIONS {#mbo3988-sec-0022}
==============

Gaining a comprehensive understanding of the biology of *Mk* is important to address the public health challenges arising from this poorly studied NTM pathogen. This understanding will help advance our preparedness against the development of multidrug resistant *Mk* CPD, a likely collateral outcome of the pervasive use of anti‐TB drugs to curb the TB epidemic. In particular, a deeper knowledge of *Mk* gene function is needed to help illuminate avenues to new and more effective therapeutics. The establishment of the ϕMycoMarT7 system as an effective mutagenesis tool in *Mk* sets the stage for further use of powerful, genome‐wide scale genetic approaches to accelerate the unraveling of gene function in this pathogen. The use of the ϕMycoMarT7 system reported herein led to the discovery of a role of the conserved mycobacterial *B11* sRNA gene in determination of (macro)colony morphology features and biofilm formation. It also permitted the identification of ≈10,000 intragenic Tn insertions that do not impede growth in vitro. These findings expand our knowledge of *Mk* gene function. Finally, the demonstration of the susceptibility of GM larvae to *Mk* opens the possibility of using this simple and economical invertebrate infection model system for virulence assessment of *Mk* mutants and in vivo evaluation of novel antimicrobial lead compounds against *Mk*.
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DATA AVAILABILITY STATEMENT {#mbo3988-sec-0028}
===========================

All data are provided in full in this paper with the exception of the data in Table S1 (Location of intragenic and intergenic transposon insertion sites in the chromosome of *M. kansasii*) and Table S2 (Location of intragenic and intergenic transposon insertion sites in the plasmid pMK12478 of *M. kansasii*), which are available in the Zenodo repository at <https://doi.org/10.5281/zenodo.3561175>.
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###### 

Bacterial strains

  Strain                               Characteristics                                                                                                                                                                                             Source
  ------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------
  *Mycobacterium kansasii*             Wild type, subtype 1, type strain (ATCC^®^ 12478™)                                                                                                                                                          American Type Culture Collection
  *M. kansasii* wt‐v                   *M. kansasii* carrying empty vector pML1335^Δ^ *^xylE^* integrated at the phage L5 *attB* integration site                                                                                                  This study
  *M. kansasii* 13D6                   *M. kansasii* carrying a Tn insertion upstream of *B11* (*ncMKAN_RS112130c*)                                                                                                                                This study
  *M. kansasii* 13D6‐v                 *M. kansasii* 13D6 carrying empty vector pML1335^Δ^ *^xylE^* integrated at the phage L5 *attB* integration site                                                                                             This study
  *M. kansasii* 13D6‐c                 *M. kansasii* 13D6 carrying complementation plasmid pML‐B11 integrated at the phage L5 *attB* integration site                                                                                              This study
  *Mycobacterium smegmatis* mc^2^155   Wild‐type laboratory strain (ATCC^®^ 700084™)                                                                                                                                                               American Type Culture Collection
  *Escherichia coli* DH5α              Strain used for general cloning applications                                                                                                                                                                Thermo Fisher Scientific, Inc.
  *E. coli* DH5α λpir                  Strain used for rescue cloning of Tn‐containing genomic fragments. The strain containing the *pir* gene required for replication of plasmids with the R6K‐derived origin of replication present in the Tn   Thermo Fisher Scientific, Inc.
  *E. coli* K12 dam^−^/dcm^−^          Strain used for propagation of plasmids free of Dam and Dcm methylation                                                                                                                                     New England BioLabs, Inc.

John Wiley & Sons, Ltd

###### 

Oligonucleotides

  Name         Sequence (5′ → 3′)                                                      Comments
  ------------ ----------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GG1          GACTGGCTGCTATTGGGCGAAG                                                  Primers for PCR‐based generation of Tn‐specific probe
  GG2          AGAAGGCGATAGAAGGCGATG                                                   
  CB2b         CGCTTCCTCGTGCTTTACGGTATCGC                                              Primers for sequencing Tn‐genome junctions. CB2b and CB2 bind the Km resistance gene and the oriR6K origin of replication, respectively
  CB2          GAGATAGGGTTGAGTGTTGTTCC                                                 
  CB3          AT**GCGGCCGC**TTCGAATACGTATCATCATCGCCAACACTCCGGGACCAAGGGT               Primers for PCR‐based generation of the 520‐bp chromosomal fragment carried by pML‐B11; genome coordinates 2809862--2810381; NotI and BspHI sites used in cloning are in bold in CB3 and CB7, respectively
  CB7          GA**TCATGA**GGACGGTCACCAATCAAGCATAGGT                                   
  CB10         GGCCAGCCCCGTACTCTCGAC                                                   RT‐qPCR primers for *MKAN_RS24220* (*sigA*); 135‐bp amplicon; genome coordinates 5589258--5589392
  CB11         ATCCAGGTAGTCGCGCAGGACT                                                  
  CB8c         CATTACTCGGCCTAGAGCCGAGGGTGCATC                                          Primers used for PCR‐based generation of *Mk* B11‐specific probe for northern analysis and as RT‐qPCR primers for *Mk B11*; 100‐bp amplicon; genome coordinates 2810109--2810208
  CB9c3        AAAAGGGACGACCCCCGCCAGGG                                                 
  CB49a        CGCCGACCTCGTTGTCCTGGTCT                                                 RT‐qPCR primers for *MKAN_RS12130*; 104‐bp amplicon; genome coordinates 2809046--2809149
  CB50a        CCAGCCCCAGGTTGGGGTTGA                                                   
  CB43a        GCGCGGTTGGCAGGTGTTGTCATT                                                RT‐qPCR primers for *MKAN_RS12135*; 115‐bp amplicon; genome coordinates 2811070--2811184
  CB44a        GGCCAGCGCACTGACTCCCA                                                    
  IS5          AATGATACGGCGACCACCGA                                                    Adapter‐specific forward primer used in both PCR reaction rounds (PCR‐1 and PCR‐2) to generate next‐generation Tn‐specific deep sequencing libraries on the Illumina platform.
  CB1          CGAGATAGGGTTGAGTGTTGTTC                                                 First Tn‐specific reverse primer used in PCR‐1 to generate next‐generation Tn‐specific deep sequencing libraries on the Illumina platform
  CB25.3_R     *CAAGCAGAAGACGGCATACGAGAT* [ATCAGT]{.ul}ATCT**CCGGGGACTTATCAGCCAACC**   Second Tn‐specific reverse primer used in PCR‐2. The primer has the Illumina flow cell sequence tag (italicized), followed by a sample barcode (underlined), followed by a random filler sequence (four nucleotides), followed by a Tn‐specific sequence (21 nucleotides; in bold). This will generate Tn‐specific deep sequencing libraries on the Illumina platform
  CB44.3_R     *CAAGCAGAAGACGGCATACGAGAT* [ATTATA]{.ul}ATCT**CCGGGGACTTATCAGCCAACC**   Second Tn‐specific reverse primer used in PCR‐2. The primer has the Illumina flow cell sequence tag (italicized), followed by a sample barcode (underlined, different from that in CB25.3_R), followed by the filler sequence (same as in CB25.3_R), followed by the Tn‐specific sequence (bold). This will generate Tn‐specific deep sequencing libraries on the Illumina platform
  Barcodeseq   **GGTTGGCTGATAAGTCCCCGG**AGAT                                           Tn‐specific index primer used to sequence the sample‐specific barcodes on the Illumina platform. The primer has the Tn‐specific sequence (bold) followed by the filler sequence
  SP2          ATCT**CCGGGGACTTATCAGCCAACC**                                           Tn‐specific read 2 primer used to initiate the paired‐end sequencing on the Illumina platform. The primer has the filler sequence followed by the Tn‐specific sequence (bold)

John Wiley & Sons, Ltd

 {#mbo3988-sec-0039}

![Section of the original screen plate showing the abnormal macrocolony morphology phenotype of *Mycobacterium kansasii* 13D6. Scale bar = 2 mm](MBO3-9-e988-g008){#mbo3988-fig-0008}

![The transposon insertion in *Mycobacterium kansasii* 13D6 does not compromise planktonic growth, nor does it affect cell morphology. (a) Representative phase contrast (PC) and differential interference contrast (DIC) microscopy images showing cells from exponentially growing cultures of the WT (left) and mutant (right) strains. Scale bars = 5 µm. Images were acquired using a Nikon Eclipse Ti inverted microscope (Nikon Instruments Inc.) (b) Growth curves of *Mk* strains. WT, wt‐v; M, 13D6‐v; and C, 13D6‐c. The growth curve data were generated in a multiwell plate‐based growth assay as described in Section [2](#mbo3988-sec-0002){ref-type="sec"}. Values of each time point represent mean ± *SE* of three independent growth curves](MBO3-9-e988-g009){#mbo3988-fig-0009}

![Southern blot hybridization analysis of *Mycobacterium kansasii* 13D6. Agarose gel electrophoresis of SacII‐digested genomic DNA (left panel) and southern blot membrane after hybridization with a Tn‐specific probe (right panel). Lanes: L, DNA molecular weight ladder; WT, WT strain; M, 13D6 mutant](MBO3-9-e988-g010){#mbo3988-fig-0010}

![Conservation of the *B11* gene locus in mycobacteria. (a) Sequence alignment of *Mycobacterium tuberculosis B11*, *Mycobacterium kansasii B11*, and predicted orthologs in other mycobacteria. (b) Sequence alignment of *B11* promoter regions. Gray shading highlights identity with the *Mtb* sequence. Asterisks below the alignment indicate 100% conservation. The bar under the alignment of *B11* orthologs marks the sequence annotated for *Mtb B11*. Abbreviations to the left and chromosomal coordinates to the right of the sequences correspond to the following bacteria and NCBI reference sequences, respectively. *Mtb*: *M. tuberculosis* strain H37Rv, NC_000962.3; *Mk*: *M. kansasii* strain ATCC 12478, NC_022663.1; *Mb*: *Mycobacterium bovis* strain AF2122/97, NC_002945; BCG: *M. bovis* BCG Pasteur 1173P2, NC_008769.1; *Mm*: *Mycobacterium marinum* strain M, NC_010612.1; *Mu*: *Mycobacterium ulcerans* strain Agy99, NC_008611.1; *Mp*: *Mycobacterium parascrofulaceum* strain ATCC BAA‐614 SCAFFOLD1, NZ_GG770553.1; *Ma*: *Mycobacterium avium* strain 104, NC_008595.1; *Mc*: *Mycobacterium columbiense* strain CECT 3035, NZ_CP020821.1; *Mi*: *Mycobacterium intracellulare* strain ATCC 13950, NC_016946.1; *Ms*: *Mycobacterium sinense* strain JDM601, NC_015576.1; *Mab*: *Mycobacterium abscessus* strain ATCC 19977, NC_010397.1; *Mt*: *Mycobacterium thermoresistible* strain NCTC10409, NZ_LT906483.1; JLS: *M*. sp. JLS, NC_009077.1; *Mn*: *Mycobacterium neoaurum* strain VKM Ac‐1815D, NC_023036.2; *Msm*: *Mycobacterium smegmatis* strain mc^2^155, NC_018289.1; *Mph*: *Mycobacterium phlei* strain NCTC8151, NZ_LR134347.1; *Mr*: *Mycobacterium rhodesiae* strain NBB3, NC_016604.1; *Mg*: *Mycobacterium gilvium* strain PYR‐GCK, NC_009338.1; and *Mv*: *Mycobacterium vanbaalenii* strain PYR‐1, NC_008726.1](MBO3-9-e988-g011){#mbo3988-fig-0011}

![Mycobacteriophage L5 integration *attB* site in *Mycobacterium kansasii*. Alignment of the 62‐bp *attB* site in *Mycobacterium smegmatis* strain mc^2^155 (*Msm*, NCBI reference sequence: NC_008596.1) and the predicted *attB* site in *M. kansasii* (*Mk*, NCBI reference sequence: NC_022663.1). Longer bar, 43‐bp *attB* common core. Shorter bar, 29‐bp necessary and sufficient for *attB* function. Chromosomal coordinates are indicated](MBO3-9-e988-g012){#mbo3988-fig-0012}

![Histograms showing overviews of frequency distributions of Tn insertions and TA dinucleotide sites along the chromosome (a) and the plasmid pMK12478 (b) of *Mycobacterium kansasii*. The data of the Tn insertions for the chromosome and plasmid are derived from Tables S1 and S2, respectively. The data of TA dinucleotide sites for the chromosome and plasmid are derived from NCBI Reference Sequences NC_022663.1 and NC_022654.1, respectively. The data presented for the chromosome and plasmid are organized in bins of 50,000 and 2,500 bp, respectively.](MBO3-9-e988-g013){#mbo3988-fig-0013}

Generation of fragment libraries for ϕMycoMarT7 transposon insertion sequencing using illumina next‐generation sequencing technology {#mbo3988-sec-0030}
====================================================================================================================================

A. Critical materials and reagents required {#mbo3988-sec-0031}
-------------------------------------------

KAPA HyperPlus Kit (Cat. no.: KR1145, Kapa Biosystems)Kapa Beads/SPRI (Cat. no.: KK8000, Kapa Biosystems)Magnetic separation rackOneTaq Hot Start DNA Polymerase (Cat. no.: M0481S, NEB)Qubit dsDNA HS Assay Kit (Cat. no.: Q32851, Thermo Fisher Scientific)Transposon specific primers: IS5; CB1; CB25.3_R; CCB44.3_R; barcodeseq; and SP2 (see Table [A2](#mbo3988-tbl-0003){ref-type="table"} in Appendix [1](#mbo3988-app-0001){ref-type="app"})Input DNA, 100--500 ng

B. Enzymatic fragmentation {#mbo3988-sec-0032}
--------------------------

Add the following components in the order noted. Keep tubes on ice.

ComponentVolume (µl)Input DNA in water (if required to make the volume higher)11.7KAPA fragmentation buffer (10×)1.7KAPA fragmentation enzyme3.3Total volume16.7

Vortex gently and spin down briefly. Return the tubes to ice. Proceed immediately to the next step.Incubate the tubes in a thermocycler for 4 min at 37°C for a DNA input of 10 ng or for 15 min at 37°C for a DNA input of 500 ng. The fragmentation target size is 350 bp.

C. End repair and A‐tailing {#mbo3988-sec-0033}
---------------------------

In the same tube in which enzymatic fragmentation was performed, assemble each end repair and A‐tailing reactions. Keep tubes on ice. (Same composition for 10 and 500 ng of DNA input.)

ComponentVolume (µl)Fragmented DNA16.7End repair & A‐tailing buffer2.3End repair & A‐tailing enzyme mix1Total volume20

Vortex gently and spin down briefly. Return the reaction tubes to ice.Incubate in a thermocycler at 65°C for 30 min. Hold at 4°C.Proceed immediately to the next step.

D. Adapter ligation {#mbo3988-sec-0034}
-------------------

Take 1.8 µl of a 25‐µM adapter stock tube and make the volume up with water such that the final volume is 5 µl.In the same tube in which the end repair and A‐tailing were performed, add the following.

ComponentVolume (µl)End repair and A‐tailing reaction product20Adapter stock5PCR‐grade water1.7Ligation buffer10DNA ligase3.3Total volume40

Mix thoroughly and centrifuge briefly.Incubate at 20°C for 15 min. Proceed immediately to next step.

E. Post‐ligation cleanup {#mbo3988-sec-0035}
------------------------

To the same tube, add the following.

ComponentVolume (µl)Adapter ligated reaction product40KAPA beads32

Mix thoroughly by vortexing and pipetting up and down multiple times. Incubate for 5 min at room temperature.Place the tube on a magnet rack and wait until the supernatant is clear. Carefully remove and discard the supernatant.Keep the tube on the magnet rack and add 200 µl of 80% ethanol.Carefully remove and discard the ethanol.Repeat steps 15--16 for a total of 2 washes.Dry the beads for 2 min to evaporate any residual ethanol.Remove the tubes from the magnet rack and resuspend beads in 12 µl of nuclease‐free water.Incubate the tube at room temperature for 2 min to elute DNA off the beads.Place the tube on a magnet rack and wait for the supernatant to be clear.Transfer the clear supernatant to a fresh tube.

F. First transposon‐specific PCR---PCR‐1 {#mbo3988-sec-0036}
----------------------------------------

Set up and run PCR‐1 as follows.

ReagentVolume (µl)OneTaq polymerase10PCR‐grade water3Primer mix: IS5 + CB1; 10 µM each2Library from step 225

TemperatureTimeCycles94˚C30 s194˚C15 s1060˚C30 s1068˚C45 s1068˚C5 min14˚CHold---

Perform a post‐PCR cleanup. To the 20 µl PCR 1 reaction, add 14 µl of KAPA beads and mix well. Repeat steps 13--22, but elute in 15 µl of nuclease‐free water.

G. Second transposon‐specific PCR---hemi‐nested PCR‐2 {#mbo3988-sec-0037}
-----------------------------------------------------

Set up and run PCR‐2 as follows.

ReagentVolume (µl)OneTaq polymerase10PCR‐grade water3Primer mix: IS5 + CB25.3_R or CB44.3_R; 10 µM each2Cleaned PCR‐1 product from step 245

TemperatureTimeCycles94˚C30 s194˚C15 s1560˚C30 s1568˚C45 s1568˚C5 min14˚CHold---

H. Final library QC {#mbo3988-sec-0038}
-------------------

![](MBO3-9-e988-g014.jpg "image")

Analyze 3 µl of PCR‐2 reaction by agarose gel electrophoresis. When DNA of transposon mutant pools is used, a library‐like smear in the transposon enriched library should be seen. The smear should not be present for controls done with wild‐type DNA as input. See example image; lanes: M, GeneRuler 1 kb Plus DNA Ladder (Thermo Fisher Scientific); 1, sample with DNA of *M. kansasii* transposon mutant pool as input DNA; 2, sample with DNA of *M. kansasii* wild type as input DNA; 3, [n]{.smallcaps}o DNA template PCR control.Clean the final PCR‐2 reaction. Repeat step 24.Using 1 µl from cleaned PCR‐2 and Qubit dsDNA HS Assay Kit, check the concentration of the library.Use another 1 µl from cleaned PCR‐2 to verify for the library size on the Agilent Bioanalyzer.The final library is then sequenced as described in the Materials and Methods section of the manuscript proper.
